NEW YORK (dpa-AFX Broker) - The Canadian bank RBC has upgraded Evotec from "Sector Perform" to "Outperform" and left the price target at 18.60 euros after the share price slide in connection with the surprising resignation of the company's CEO. There are risks with regard to the drug researcher's earnings target (EBITDA) for 2025 and he is still skeptical about the company's forecast for the current year, analyst Charles Weston wrote in a study published on Thursday. However, the current valuation takes too much account of these risks and the company's debt-free balance sheet allows for flexibility, he said./la/ajx

Publication of the original study: 17.01.2024 / 18:14 / EST First transmission of the original study: 18.01.2024 / 00:45 / EST

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------